An improved human tumor stem cell assay in ovarian cancer.
To evaluate the effect of improved growth rates of ovarian cancers in the human tumor stem cell assay and its value in predicting clinical chemotherapy response, we studied 59 assays in 54 patients. A total of 81.6% of solid specimens and 85.7% of ascites specimens were successfully cultured and yielded an overall growth rate of 82.9%. Simultaneous primary and metastatic cultures were concordant for chemosensitivity in 80% (n = 16). The patients were evaluated for previous chemotherapy, residual volume of tumor, histologic type, and grade, and these were not statistically different between clinical responders and nonresponders. In vivo-in vitro correlations were made in 27 patients and yielded a predictive response of 13% and predictive resistance of 86% at 70% colony inhibition and 31% and 71% at 50% colony inhibition. Improved growth rates therefore did not result in better predictive correlations. The reported experience in ovarian cancer is summarized and the current status of the human tumor stem cell assay is reviewed.
D003114:Colony-Forming Units Assay; D005260:Female; D006801:Humans; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000503:physiopathology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D014410:Tumor Stem Cell Assay